Takiishi T, Cook DP, Korf H, Sebastiani G, Mancarella F, Cunha JP, et al. Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting Lactococcus lactis in combination with low-lose anti-CD3 depends on the Induction of Foxp3-Positive T cells. Diabetes. 2017;66(2):448-459.

Read Article

Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes. 2014;63(8):2876-2887.

Read Article

Limaye SA, Haddad RI, Cilli F, Sonis ST, Colevas AD, Brennan MT et al. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013;119(24):4268-4276.

Read Article

Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, et al. Reversal of autoimmune diabetes by restoration of antigen- specific tolerance using genetically modified Lactococcus lactis in mice. Journal of Clinical Investigation. 2012 May 1;122(5):1717-25

Read Article

Caluwaerts S, Vandenbroucke K, Steidler L, Neirynck S, Vanhoenacker P, Corveleyn S, et al. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncology. 2010 Jul;46(7):564-70.

Read Article

Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunology. 2010 Jan;3(1):49-56.

Read Article

Huibregtse IL, Marietta EV, Rashtak S, Koning F, Rottiers P, David CS, et al. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic ABo DQ8 transgenic mice. Journal of Immunology. 2009 Aug 15;183(4):2390-6.

Read Article

Rottiers P, De Smedt T and Steidler L. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. International Reviews of Immunology. 2009;28:465-486.

Read Article

Huibregtse IL, Snoeck V, de Creus A, Braat H, De Jong EC, Van Deventer SJ, et al. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology. 2007;133:517-528.

Read Article

Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with Transgenic bacteria expressing interleukin-10 in Crohn's disease. Clinical Gastroenterology and Hepatology. 2006;4:754-759.

Read Article

Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology. 2004;127:502-513.

Read Article

Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nature Biotechnology. 2003;21:785-789.

Read Article

Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352-1355.

Read Article

Steidler L, Wells JM, Raeymaekers A, Vandekerckhove J, Fiers W, Remaut E. Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis. Applied and Environmental Microbiology. 1995;61(4):1627-1629.

Read Article